Jacob Borodovsky is a PhD candidate at The Dartmouth Institute and at the Center for Technology and Behavioral Health. As a graduate student, he has conducted epidemiological research aimed at evaluating the effects of state-level cannabis legalization in the United States. He is particularly interested in determining how the idiosyncratic regulatory infrastructures that underlie each state's medical and/or recreational legal cannabis laws, differentially affect population-level use of novel methods of cannabis administration (e.g., vaping, edibles, dabs). His ultimate goal is to conduct research that can be used to help develop rational, data-driven, and public health-oriented regulatory models for legal cannabis.
Jacob’s other line of research concerns buprenorphine—a medication used to treat opioid use disorder. The unique regulations that guide prescribing and dispensation of this medication offer public health advantages over the traditional methadone-model treatment. However, there are still barriers to effective buprenorphine treatment delivery for clinical subgroups—particularly adolescents and young adults. Jacob has worked towards developing novel technology-based buprenorphine treatment platforms and establishing the utility of longer-term buprenorphine treatment for young people with opioid use disorders.
Jacob received his B.A. in Clinical Psychology from Tufts University in 2012.
Jacob’s contributions to the literature can be found here.
Knapp AA, Lee DC, Borodovsky JT, Auty SG, Gabrielli J, Budney AJ
J Adolesc Health|2018 Sep 8
Brunette MF, Borodovsky JT, Myers M, Budney AJ
Psychiatr Serv|2018 Sep 6
Borodovsky JT, Budney AJ
Int Rev Psychiatry|2018 Jun
Borodovsky JT, Marsch LA, Budney AJ
JMIR Public Health Surveill|2018 May 2
Borodovsky JT, Levy S, Fishman M, Marsch LA
J Addict Med|2018 May/Jun